Cervomed vs Rallybio
Cervomed is the larger business, with $4.0m of revenue in fiscal 2025 against $858,000 for Rallybio (4.7 times as much). Rallybio grew faster (34.9% against -58.9%). Cervomed kept more of each dollar of sales as profit: a net margin of -673.1% against -1046.4%. Cervomed carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | CervomedCRVO, 2025 | RallybioRLYB, 2025 |
|---|---|---|
| Revenue | $4.0m | $858,000 |
| Revenue growth | -58.9% | 34.9% |
| Net income | −$27.0m | −$9.0m |
| Operating margin | -706.2% | -3853.6% |
| Net margin | -673.1% | -1046.4% |
| Return on equity | -93.9% | -15.0% |
| Free cash flow | −$23.4m | −$29.8m |
| Cash | $8.2m | $31.4m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 15 | 14 |
| Market value | $21.0m | $85.2m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 19 buys, 0 sales | 14 buys, 2 sales |